DR REDDYS LABORATORIES LTD — Capital/Financing Update 2021

Sep 9, 2021

==> picture [453 x 126] intentionally omitted <==

September 9, 2021

To, The Secretary BSE Limited National Stock Exchange of India Ltd. New York Stock Exchange Inc. NSE IFSC Limited

Dear Sir/ Madam,

Sub: Intimation

This is in reference to our press release dated August 4, 2021, wherein we announced the sale of rights for ELYXYB (celecoxib oral solution) 25 mg/mL for U.S. and Canada territory to BioDelivery Sciences International, Inc. (BDSI).

In this regard, we would now like to inform you about the closure of the transaction with BioDelivery Sciences International, Inc. (BDSI). Such closure was subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

This is for your information and records.

Yours faithfully, For Dr. Reddy's Laboratories Limited

==> picture [115 x 29] intentionally omitted <==

==> picture [115 x 29] intentionally omitted <==

==> picture [115 x 28] intentionally omitted <==

Sandeep Poddar Company Secretary